22157.jpg
Anti-CD279 (PD-1) Antibody Drug Pipeline Research Report 2024: Insights on 40+ Companies Featuring GlaxoSmithKline, Innovent Biologics, BeiGene, and Shanghai Junshi Biosciences
April 11, 2024 09:15 ET | Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Anti-CD279 (PD-1)...
New Logo.png
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
April 11, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
PV-10 demonstrated significant anti-tumor activity in vivo in head and neck cancers KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
22157.jpg
Global Orphan Drug Sector Poised for Growth Amidst Unmet Rare Disease Needs
April 05, 2024 04:04 ET | Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Global Orphan Drug Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study provides critical insights into the...
Active Pharmaceutical Ingredient CDMO Market
Global Active Pharmaceutical Ingredient CDMO Market Projected to Reach USD 164.5 Billion by 2030
March 29, 2024 05:36 ET | Research and Markets
Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow,...
New Logo.png
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
March 27, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
New Provectus Spinout Company Would Commercialize Combination Therapy of University’s Light Source Medical Device and Provectus’s Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March 27,...
New Logo.png
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
March 12, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office...
22157.jpg
Generative AI in the Global Pharmaceutical Market 2024-2030 - Deep Learning Leads Growth, with the Drug Discovery Segment Dominating Amid Rising Demand for Large Dataset Analysis
March 08, 2024 07:09 ET | Research and Markets
Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Generative AI in Pharmaceutical Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...
New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
March 07, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in vivo KNOXVILLE, TN, March 07,...
New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
February 29, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
Preclinical Research on Full-Thickness Cutaneous Wound Healing KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB:...
22157.jpg
Global PRMT5 Targeted Therapy Market & Clinical Trials Insights 2024: Innovation and Potential in Oncology and Beyond
February 29, 2024 04:06 ET | Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering. ...